Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alector
Biotech
Alector halves staff after GSK-partnered antibody fails in ph. 3
To pivot away from latozinemab, the Bay Area biotech is laying off 49% of its staff, while the company’s R&D head is resigning effective Dec. 22.
Darren Incorvaia
Oct 22, 2025 11:23am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
AbbVie dumps Alector's Alzheimer's immunotherapy after phase 1
Jul 8, 2022 6:04am
With GSK, Alector to capitalize on big moment in Alzheimer's
Jan 27, 2022 9:35am
COVID-19 vaccine mandates a mixed bag in biotech
Aug 11, 2021 8:10am
Alector bolsters 'immuno-neurology' approach with early data
Jul 30, 2021 10:15am
